The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry
Abstract
Abstract Purpose This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced (i.e. metastatic) breast cancer (ABC). Methods All patients diagnosed with HR+/HER2- ABC who received endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-given systemic therapy between 2007 and 2020 in the Netherlands were identified from the Southeast Netherlands Advanced Breast Cancer (SONABRE) registry (NCT03577197). Patients with a recorded BMI were categorised as underweight (2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), or obese (≥30 kg/m2). Overall survival (OS) and progression-free survival (PFS) were compared between BMI classes using multivariable Cox regression analyses. Results This study included 1,456 patients, of whom 35 were underweight, 580 normal weight, 479 overweight, and 362 obese. No differences in OS were observed between normal weight patients and respectively overweight (HR=0.99; 95% CI: 0.85-1.16) and obese patients (HR=1.04; 95% CI: 0.88-1.24). However, the OS of underweight patients (HR=1.45; 95% CI: 0.97-2.15) tended to be worse than the OS of normal weight patients. When compared with normal weight patients, the PFS was similar in underweight (HR=1.05; 95% CI: 0.73-1.51), overweight (HR=0.90; 95% CI: 0.79-1.03), and obese patients (HR=0.88; 95% CI: 0.76-1.02). Conclusion In this study among…
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.